Alpha 2.0
Login Register
» Articles » PMID: 27248430

Quantitative Measurements of Enhancement on Preprocedure Triphasic CT Can Predict Response of Colorectal Liver Metastases to Radioembolization

Overview
Journal AJR Am J Roentgenol
Specialties Oncology
Radiology
Date 2016 Jun 2
PMID 27248430
Citations 19
Authors
F Edward Boas
Lynn A Brody
Joseph P Erinjeri
Hooman Yarmohammadi
Waleed Shady
Sirish Kishore
Constantinos T Sofocleous
Affiliations
Soon will be listed here.
Abstract

Objective: Colorectal liver metastases (CLM) have a variable response to radioembolization. This may be due at least partly to differences in tumor arterial perfusion. The present study examines whether quantitative measurements of enhancement on preprocedure triphasic CT can be used to predict the response of CLM to radioembolization.

Materials And Methods: We retrospectively reviewed patients with CLM treated with radioembolization who underwent pretreatment PET/CT and triphasic CT examinations and posttreatment PET/CT examinations. A total of 31 consecutive patients with 60 target tumors were included in the present study. For each tumor, we calculated the hepatic artery coefficient (HAC), portal vein coefficient (PVC), and arterial enhancement fraction (AEF) based on enhancement measurements on pretreatment triphasic CT. HAC and PVC are estimates of the hepatic artery and portal vein blood supply. AEF, which is the arterial phase enhancement divided by the portal phase enhancement, provides an estimate of the hepatic artery blood supply as a fraction of the total blood supply. For each tumor, the metabolic response to radioembolization was based on findings from the initial follow-up PET/CT scan obtained at 4-8 weeks after treatment.

Results: A total of 55% of CLM had a complete or partial metabolic response. Arterial phase enhancement, the HAC, and the PVC did not predict which tumors responded to radioembolization. However, the AEF was statistically significantly greater in tumors with a complete or partial metabolic response than in tumors with no metabolic response (i.e., those with stable disease or disease progression) (p = 0.038). An AEF of less than 0.4 was associated with a 40% response rate, whereas an AEF greater than 0.75 was associated with a 78% response rate.

Conclusion: Response to radioembolization can be predicted using the AEF calculated from the preprocedure triphasic CT.

Citing Articles

Quantitative and qualitative evaluation of liver metastases with intraprocedural cone beam CT prior to transarterial radioembolization as a predictor of treatment response.

Messmer F, Zgraggen J, Kobe A, Chaykovska L, Puippe G, Reiner C Res Diagn Interv Imaging. 2024; 1:100005.

PMID: 39077371 PMC: 11265323. DOI: 10.1016/j.redii.2022.100005.

Portal Venous and Hepatic Arterial Coefficients Predict Post-Hepatectomy Overall and Recurrence-Free Survival in Patients with Hepatocellular Carcinoma: A Retrospective Study.

Li Y, Wu S, Wu Y, Zhang W, Wang Y, Li Y J Hepatocell Carcinoma. 2024; 11:1389-1402.

PMID: 39011125 PMC: 11247128. DOI: 10.2147/JHC.S462168.

The Influence of Additional Treatments on the Survival of Patients Undergoing Transarterial Radioembolization (TARE).

Quartuccio N, Ialuna S, Scalisi D, DAmato F, Barcellona M, Bavetta M Curr Oncol. 2024; 31(3):1504-1514.

PMID: 38534947 PMC: 10969045. DOI: 10.3390/curroncol31030114.

An interpretable machine learning model based on contrast-enhanced CT parameters for predicting treatment response to conventional transarterial chemoembolization in patients with hepatocellular carcinoma.

Zhang L, Jin Z, Li C, He Z, Zhang B, Chen Q Radiol Med. 2024; 129(3):353-367.

PMID: 38353864 DOI: 10.1007/s11547-024-01785-z.

Arterial enhancement fraction in evaluating the therapeutic effect and survival for hepatocellular carcinoma patients treated with DEB-TACE.

Chai B, Xiang D, Wang W, Ren Y, Wang F, Wang J Cancer Imaging. 2022; 22(1):38.

PMID: 35908071 PMC: 9338623. DOI: 10.1186/s40644-022-00477-z.

References
1.
Morsbach F, Sah B, Spring L, Puippe G, Gordic S, Seifert B . Perfusion CT best predicts outcome after radioembolization of liver metastases: a comparison of radionuclide and CT imaging techniques. Eur Radiol. 2014; 24(7):1455-65. DOI: 10.1007/s00330-014-3180-3. View
2.
Fendler W, Philippe Tiega D, Ilhan H, Paprottka P, Heinemann V, Jakobs T . Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J Nucl Med. 2013; 54(8):1202-8. DOI: 10.2967/jnumed.112.116426. View
3.
Wahl R, Jacene H, Kasamon Y, Lodge M . From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50 Suppl 1:122S-50S. PMC: 2755245. DOI: 10.2967/jnumed.108.057307. View
4.
Chua T, Bester L, Saxena A, Morris D . Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. J Cancer Res Clin Oncol. 2010; 137(5):865-73. DOI: 10.1007/s00432-010-0948-y. View
5.
Boas F, Kamaya A, Do B, Desser T, Beaulieu C, Vasanawala S . Classification of hypervascular liver lesions based on hepatic artery and portal vein blood supply coefficients calculated from triphasic CT scans. J Digit Imaging. 2014; 28(2):213-23. PMC: 4359206. DOI: 10.1007/s10278-014-9725-9. View